Millicent patent expiration

1. Femring patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5855906 MILLICENT Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors
Dec, 2015

(8 years ago)




Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 March, 2003

Treatment: Method of releasing 17-beta oestradiol precursor in a substantially zero order pattern for at least three weeks

Dosage: INSERT, EXTENDED RELEASE

More Information on Dosage

FEMRING family patents

Family Patents

2. Intrarosa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions
Aug, 2028

(4 years from now)

US8957054 MILLICENT Pharmaceutical compositions
Jan, 2030

(5 years from now)

US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2021

Drugs and Companies using PRASTERONE ingredient

NCE-1 date: 16 November, 2020

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT

More Information on Dosage

INTRAROSA family patents

Family Patents